Commercialization: Immediate Short-Term, Vast Long-Term Potential

Vaccinogen’s OncoVAX® vaccine offers outstanding potential for commercial success, both in the short term and long term. Its approval for commercial use in Switzerland will yield revenues in Q3 2008. A vast global market could unfold as soon as 2011, if FDA approval is achieved as expected.

Vaccinogen has met many of the challenges of commercialization

Automated identity, potency & product characterization for a patient-specific tumor vaccine;
Vaccinogen has a patented sterile manufacturing process for patient-specific tumor vaccines, with the participation of the surgeon and the pathologist in the operating room;
Regulatory approval of commercial manufacturing facility in Holland by Dutch/Swiss Authorities; and
900/m² (9600 ft²) facility has five class B manufacturing suites and two class C QC laboratories with a capacity to produce 3,500 OncoVAX® vaccines per year ($130M/£65M) – a production amount sufficient to cover the pivotal Phase IIIb clinical trial and the commercial sales of OncoVAX® in Switzerland and Eastern Europe.